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KAJIAN CIRI-CIRI ANTI-KANSER BENZYL-O-VANILLIN DAN 
TERBITANNYA 
 
Benzyl-o-vanili dan nukleus benzimidazole adalah pharmacophore yang 
penting dalam penemuan ubatan kerana mempunyai kepentingan ubat yang 
signifikan. Oleh yang demikian, kita menerokai aktiviti anti-kanser daripada tiga 
sebatian iaitu 2 - (2-benzyloxy-3-metoksifenil)-1H-benzimidazole, 2MP, N-1-(2-
benzyloxy-3-methoxybenzyl) -2 - (2-benzyloxy-3 -metoksifenil)-1H-benzimidazole, 
2XP, dan (R) dan (S) -1 - (2-benzyloxy-3-metoksifenil) -2, 2, 2-trichloroethyl 
benzenesulfonate, 3B dan membandingkan aktiviti mereka dengan 2-benzyloxy- 3-
methoxybenzaldehyde, (BN1) iaitu sebatian induk. 2XP dan 3B yang telah ditemui 
memberi sitotoksik yang selektif terhadap sel leukemia U937 menyebabkan kematian 
sel melalui apoptosis dengan mengaktifkan kegiatan caspase 9.  
Kajian pengikatan DNA terutamanya dengan ujian titrasi keseimbangan 
pengikatan menunjukkan aktiviti pengikatan DNA dengan konstan pengikatan 
7.39μM/bp dan 6.86μM/bp untuk 3B dan 2XP masing-masing. Kajian viskometri 
menunjukkan bahawa 3B dan 2XP mengikat terutamanya di kawasan-kawasan alur. 
Mutagenisiti 3B yang lebih tinggi menunjukkan bahawa sebatian ini menyasarkan 
N7  dalam guanina dalam alur utama dan GC di alur kecil yang lebih luas manakala 
kekurangan keputusan mutagen yang signifikan oleh 2XP menunjukkan bahawa 
sebatian ini mungkin menyasarkan urutan kaya dengan AT , yang ditemui dalam 
sebahagian besar di bahagian sempit alur kecil asid nukleik.  
 xxiii 
 
Keputusan kajian kami menunjukkan bahawa benzylvanillin sahaja tidak 
mempunyai aktiviti anti-kanser kuat walaupun digabungkan dengan benzimidazole, 
tetapi setelah disubstitusi dengan benzylvanillin lain, aktiviti yang lebih kuat 
diperhatikan. Kombinasi benzylvanillin dengan benzenesulfonate juga meningkatkan 
secara signifikan aktiviti 3B kerana kehadiran benzenesulfonate membolehkannya 
untuk memiliki aktiviti alkilasi yang baik. Penemuan kajian ini menyokong hasil 
pemodelan komputer yang juga menunjukkan bahawa 3B dan 2XP mempunyai 
pengikatan DNA yang baik. Kedua-dua sebatian (2XP dan 3B) gagal untuk 
membentuk ikatan langsung dengan DNA, tidak seperti BN1 dan 2MP. Namun 
begitu, kedua-dua sebatian (BN1 dan 2MP) gagal untuk menunjukkan aktiviti 
sitotoksik.  
Oleh itu, kajian ini memberikan pendekatan baru bagi derivatif novel 
benzylvanillin sebagai agen terapeutik yang berpotensi terhadap leukemia. 
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THE STUDY OF ANTICANCER PROPERTIES OF BENZYL-O-
VANILLIN AND IT’S DERIVATIVES 
 
Benzyl-o-vanillin and benzimidazole nucleus serve as important 
pharmacophore in drug discovery as it has a significant medicinal importance. Thus 
we explored the anticancer activity of three compounds namely  2-(2-benzyloxy-3-
methoxyphenyl)-1H-benzimidazole, 2MP, N-1-(2-benzyloxy-3-methoxybenzyl)-2-
(2-benzyloxy-3-methoxyphenyl)-1H-benzimidazole, 2XP, and (R) and (S)-1-(2-
benzyloxy-3-methoxyphenyl)-2, 2, 2-trichloroethyl benzenesulfonate, 3BS and 
compared their activity to 2-benzyloxy-3-methoxybenzaldehyde, (Bn1) the parent 
compound. 2XP and 3BS were found to be selectively cytotoxic towards U937 
leukemic cell causing cell death via apoptosis by activating caspase 9 activity.  
DNA binding studies primarily by the equilibrium binding titration assay 
indicate DNA binding activity with binding constant of 7.39µM/bp and 
6.86µM/bp for 3BS and 2XP respectively.  Viscometry studies show that 3BS and 
2XP bind mainly in the groove region. The higher mutagenicity of 3BS suggests that 
this compound targets the N7 of guanine in the major groove and the GC in the wider 
minor groove while the lack of significant mutagenic outcome by 2XP 
suggests that this compound may target mainly the AT rich sequences, found 
largely in the narrow minor groove region of the nucleic acid.  
Our results show that the benzylvanillin alone have no strong anticancer 
activity even after it was combined with the benzimidazole, but after being 
 xxv 
 
disubstituted with another benzylvanillin, stronger activity was observed. Also, the 
combination of benzylvanillin with benzenesulfonate significantly improved the 
activity of 3BS as the presence of benzenesulfonate enabled it to have good 
alkylating activity. The findings of this study support our computer modeling results 
which also shows that 3BS and 2XP have good DNA binding. Both compounds 
(2XP and 3BS) failed to form any direct linkage with the DNA unlike Bn1 and 2MP. 
However these two compounds (Bn1 and 2MP) failed to show any cytotoxic activity. 
Hence, the present study provides a new insight of the novel benzylvanillin 
derivatives serving as potential therapeutic agents against leukemia. 
 1 
CHAPTER ONE 
INTRODUCTION 
1.1  Cancer Overview: 
 1.1.1  Introduction: 
Cancer is considered as the second most common cause of death after heart 
disease. From 58 million deaths worldwide in 2005, cancer accounts for 7.6 million 
(or 13%) of all deaths. Deaths due to cancers across the globe are expected to rise, 
with an estimate of 9 million people dying from cancer in 2015 (Selvan, 2007 ). 
Cancer could be defined as a group of diseases at which abnormal cells divide 
without control (U.S. Department of health and human services, 2003) . In other 
words, cancer is a disease characterized by uncoordinated and undesirable cell 
division accompanied with the spread of abnormal cells to the remote area, 
metastasis (Caligiuri, 2007b; Evert, 2010; SEER Training Modules, 2011b). 
It results from a breakdown of the regulatory mechanisms that govern normal 
cell behaviour, which are the proliferation, differentiation, and survival of individual 
cells in multicellular organisms (Bjornsti & Osheroff, 1999). Unlike normal cells, 
cancer cells are aggressive (grow and divide without respect to normal limits), 
invasive (invade and destroy adjacent tissues), and/or metastatic (spread to other 
locations in the body) (Evert, 2010). These three malignant properties of cancers 
differentiate them from benign tumors that are self-limited in their growth and do not 
invade or metastasize (Bjornsti & Osheroff, 1999). Frequently, benign tumor is 
completely enclosed in a protective capsule of tissue and it typically does not pose 
 2 
danger to human life like malignant tumors do (Bjornsti & Osheroff, 1999; Evert, 
2010; Fayed, 2009; SEER Training Modules, 2011b; U.S. Department of health and 
human services, 2003; Yu, Blanchard, Wang, & You, 2008). Over time, changes may 
take place in benign tumor cells that cause them to invade and interfere with the 
function of normal tissues (Fayed, 2009; U.S. Department of health and human 
services, 2003). 
Although cancer is often referred to a single condition, it actually described 
as a group of more than 100 different diseases that have similar characteristics 
(SEER Training Modules, 2011b). It is usually classified according to the tissue from 
which the cancerous cells originate, as well as location (Harnden, Lorenzen, Pusztai, 
& McGee, 1998). The most common type is carcinoma that develops from epithelial 
tissue lining the surfaces of certain organs, such as the lung, liver, skin, breast or the 
lining of blood vessels. Another group of cancers is sarcoma that arises from cells in 
bone, cartilage, fat, connective tissue, supportive tissue, and muscle (Harnden, et al., 
1998; U.S. Department of health and human services, 2003). 
Nearly all cancers are caused by abnormalities in the genetic material of the 
transformed cells (U.S. Department of health and human services, 2003). These 
genetic abnormalities may be due to the effects of carcinogens, such as tobacco 
smoke, radiation, chemicals and infectious agents (U.S. Department of health and 
human services, 2003). Other cancer-promoting genetic abnormalities may be 
randomly acquired through errors in DNA replication or inherited from birth. 
However, a complex interaction between carcinogens and the host genome exist that 
might explain a difference in the incidence of cancer after exposure to a known 
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carcinogen. Thus, new aspects of cancer pathogenesis needs an extensive and further 
exploration to assess the other possible pathways (Harnden, et al., 1998). 
 
 1.1.2  Cancer History: 
The signs of cancer in the bones of ancient Egyptian mummies dating back as 
far as 3000 B.C (Britannica Online, 2005). These had been described by Edwin 
Smith Papyrus in 1862 (Grant, 2001; Morton & Moore, 1997; The American Cancer 
Society Inc., 2002). This document is considered to be the oldest written description 
of cancer known to exist, described eight cases of breast tumours or ulcers in Egypt 
that were treated with cauterization. However, the document also states that there is 
no treatment for cancer at that time (Emory University, 2010; Hutchinson, 2006). 
In 50 A.D., Romans found that some tumours could be removed by surgery 
followed by cauterization, but no medicine seemed to work. They found that surgery 
sometimes increased the spread of cancer or sometimes grew again. Later on caustic 
(burning) pastes, usually containing arsenic, were used for control of more extensive 
cancer. In addition, phlebotomy (blood-letting), diet, herbal medicines, powder of 
crab and other symbolic charms were also used (Cancer Council Victoria, 2010). 
Though treatment remained the same, the development of microscopes in 
1650 A.D. had led to a major step in improving the understanding of cancer. Since 
then different school of thought regarding the causes and treatment modalities had 
evolved (Cancer Request, 2010d). 
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In 19th century, asepsis improved surgical hygiene and as the survival 
statistics went up, surgical removal of the tumour became the primary treatment for 
cancer (Britannica Online, 2005). During the same period X-ray was discovered by 
German physicist Wilhelm Conrad Roentgen. This powerful ray was being used to 
detect and effectively treat cancer (Radiology Society of North America, 2008). 
After World War II (WWII), Japanese medical community observed that the 
bone marrow of bomb victims in Hiroshima and Nagasaki was completely destroyed. 
They concluded that diseased bone marrow could also be destroyed with radiation, 
and this led to the discovery of bone marrow transplants for leukaemia (Hiroo, 1998). 
In 1939, Charles Brendon Huggins discovered that hormones were necessary 
for the growth of certain cancers and this led the groundwork for hormone therapy 
for certain cancers(Machtens, Schultheiss, Kuczyk, Truss, & Jonas, 2000; Raju, 
1998). Later on in 1946, Louis Goodman studied the chemical warfare agents during 
WWII. He discovered that nitrogen mustards could be used in the treatment of 
cancer. This is considered as the first chemotherapeutic agents against Hodgkin's 
Disease, lymphosarcoma, and leukemias (Britannica Online, 2005; Freireich, 1984; 
Goodman et al., 1984) . 
First DNA microarray chip was constructed and used to measure gene 
expression levels in plants during 1995. This technology has been advanced and used 
to study cancer in humans. Currently 'gene chips' are being investigated as a tool in 
the development of individualized treatment plans (Emory University, 2010; 
Hutchinson, 2006). 
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 1.1.3  Biology of Cancer: 
Tumorigenesis is a multistep process where genetic changes such as point 
mutation, gene amplification, translocation, deletion, and viral infection accumulate 
over time (Figure 1.1). These genetic changes, in turn, would cause downstream 
alterations in transcription, protein expression, and other cellular functions that 
eventually lead to the stepwise transformation of normal cells to malignant cells 
(Bjornsti & Osheroff, 1999). These malignant cells will soon acquire the ability to 
invade tissues, induce angiogenesis to support their own growth, and finally establish 
metastatic sites in remote organs (Yu, et al., 2008).  
There are distinct biological properties that a cell must accumulate in order to 
develop cancer (Perspectives on Cancer, 2009). These hallmarks are: 
 Self-sufficiency in growth signals, which means that cells grow even when it’s 
not getting a message to grow (Caligiuri, 2007a; Douglas Hanahan & Robert A. 
Weinberg, 2000a; Mitchell, 2007; Perspectives on Cancer, 2009). 
 Insensitivity to anti-growth signals, which means that cells ignore messages to 
stop growing (Caligiuri, 2007a; Douglas Hanahan & Robert A. Weinberg, 2000a; 
Mitchell, 2007; Perspectives on Cancer, 2009). 
 Evasion of apoptosis, which means that cells avoid all the messages to die 
(Caligiuri, 2007a; Douglas Hanahan & Robert A. Weinberg, 2000a; Mitchell, 2007; 
Perspectives on Cancer, 2009). 
 Angiogenesis, which means the ability to develop new blood vessels to get the 
nutrients that fuel continued growth and division (Caligiuri, 2007a; Douglas Hanahan 
& Robert A. Weinberg, 2000a; Mitchell, 2007; Perspectives on Cancer, 2009). 
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 Unlimited replication potential, which means that cells keep replicating without 
control (Caligiuri, 2007a; Douglas Hanahan & Robert A. Weinberg, 2000a; Mitchell, 
2007; Perspectives on Cancer, 2009). 
 Invasion and metastasis, which means that cells spread into areas where they 
should not normally present. Tissue invasion and metastasis are what make many 
cancers lethal (Caligiuri, 2007a; Douglas Hanahan & Robert A. Weinberg, 2000a; 
Mitchell, 2007; Perspectives on Cancer, 2009). 
 An inflammatory microenvironment, newly discover in 2008. The cancer-related 
inflammation contributes to proliferation and survived of malignant cells, 
angiogenesis, metastasis, subversion of adaptive immunity and reduced response to 
hormones and chemotherapeutic agents. It is induction of genetic instability by 
inflammatory mediators, leading to accumulation of random genetic alterations in 
cancer cells (Colotta, Allavena, Sica, Garlanda, & Mantovani, 2009). It was 
suspected (G. Smith & Missailidis, 2004) then represented as the seventh hallmark of 
cancer (Colotta, et al., 2009). 
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Fig. 1.1  The hallmarks of cancer (Douglas Hanahan & Robert A. Weinberg, 2000b; 
Mantovani, 2009). 
 
1.2 Cell Cycle: 
The cell cycle, or cell-division cycle, is the series of events that takes place in 
a cell leading to its division and duplication (Malumbers, 2008; J. A. Smith & 
Martin, 1973).  
The cell cycle consists of two parts or four distinct phases (Figure 1.2): the 
interphase: G1 phase, S phase (synthesis), G2 phase (collectively known as 
interphase) and M phase (mitosis): mitosis, in which the cell's chromosomes are 
divided between the two daughter cells, and cytokinesis, in which the cell's 
cytoplasm divides in half forming distinct cells (J. A. Smith & Martin, 1973). 
Activation of each phase is dependent on the proper progression and completion of 
the previous one. Cells that have temporarily or reversibly stopped dividing are said 
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to have entered a state of quiescence called G0 phase (Rubenstein & Wick, 2008). 
Table 1.1 is shown a detailed description involved in each phase. 
 
Figure 1.2 The cell cycle consists of two parts or four distinct phases: the interphase (G1 
phase, S phase (synthesis), G2 phase) and M phase (mitosis) (mitosis and cytokinesis) 
(Virtual Genetics Education Centre, 2011). 
Table 1.1 The cell cycle phases and their description (HighWire Press, 2003; 
Malumbers, 2008). 
State Phase Abbreviation Description 
quiescent/ 
senescent 
Gap 0 G0 
A resting phase where the cell has left the cycle and has 
stopped dividing. occurs in response to DNA damage or 
degradation that would make a cell's progeny nonviable; it is 
often a biochemical alternative to the self-destruction of such 
a damaged cell by apoptosis 
Interphase 
Gap 1 G1 
Cells increase in size in Gap 1. The G1 checkpoint control 
mechanism ensures that everything is ready for DNA 
synthesis. 
Synthesis S DNA replication occurs during this phase. 
Gap 2 G2 
During the gap between DNA synthesis and mitosis, the cell 
will continue to grow. The G2 checkpoint control mechanism 
ensures that everything is ready to enter the M (mitosis) 
phase and divide. 
Cell division Mitosis M 
Cell growth stops at this stage and cellular energy is focused 
on the orderly division into two daughter cells. A checkpoint 
in the middle of mitosis (Metaphase Checkpoint) ensures 
that the cell is ready to complete cell division. 
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Several cell cycle checkpoints are used by the cell to monitor and regulate the 
progress of the cell cycle. These checkpoints are designed to ensure that damaged or 
incomplete DNA is not passed on to daughter cells which may lead to tumor 
formation. The two main checkpoints exist are G1/S checkpoint also known as 
restriction point and G2/M checkpoint (Kumar, Abbas, & Fausto, 2004). 
In cancer therapy, the cells which are actively undergoing cell cycle are 
targeted as the DNA is relatively exposed during cell division and hence susceptible 
to damage by drugs or radiation. But in general, cells are most radiosensitive in late 
M and G2 phases and most resistant in late S because the resistance and sensitivity 
correlates with the level of sulfhydryl compounds in the cell which are natural 
radioprotectors and tend to be at their highest levels in S and at their lowest near 
mitosis (Rubenstein & Wick, 2008). 
 
1.3 Cell Death: 
 1.3.1 Introduction: 
Cell death is a major endpoint in toxicological assessment both in vivo and in 
vitro and numerous methods have become available for the characterization and 
quantitation of cell death. Recent developments in cell biology have made great 
strides in articulating two generally distinct modes of cell death (Poot, Pierce, & 
Kavanagh, 2002). 
In general, the cell death divided into apoptosis and necrosis, and each 
involves different biochemical features and, possibly, kinetics(Raffray & Cohen, 
 10 
1997). Necrosis appears to be a rapid response (often to exogenous agents) involving 
cellular injury, cell swelling, loss of cytoplasmic ATP, release of sequestered 
calcium, and uncontrolled activation of calcium-dependent enzymes (proteases, 
lipases and DNAases) leading to early loss of cytoplasmic membrane 
integrity(Cotran, Kumar, Collins, & Robbins, 1999). DNA single-strand breaks are 
formed, but the morphology of the cell nucleus usually remains intact (Mellor et al., 
2002; Nguyen, 2006). Cells undergoing rapid necrosis in vitro do not have sufficient 
time or energy to activate apoptotic machinery and will not express apoptotic 
markers (Nguyen, 2006). 
Apoptosis, in contrast, is a more controlled process involving a decrease in 
cell size, the loss of mitochondrial membrane potential, alterations in mitochondrial 
structure and function, altered cellular redox status (D. Green & Kroemer, 1998; D. 
R. Green & Reed, 1998), as well as activation of caspases, exposure of cell-surface 
phosphatidylserine residues, and ordered double-strand DNA fragmentation (Poot, et 
al., 2002). Cultured cells that are undergoing apoptosis in vitro eventually undergo 
secondary necrosis. Markers of apoptosis such as caspase activity may be present 
only transiently (Nguyen, 2006). 
Apoptosis has been associated with ischemic injury (like myocardial 
infarction, and reperfusion injury) (MacManus, Buchan, Hill, Rasquinha, & Preston, 
1993; Walton et al., 1997), immunoreactive and immunodegenerative states and a 
variety of neurodegenerative disorders (including Alzheimer's disease, ALS and 
motor neuron degeneration, Parkinson's disease, etc.), and retinal ganglion cell death 
in experimental glaucoma (Garcia-Valenzuela, Shareef, Walsh, & Sharma, 1995; 
Laquis, Chaudhary, & Sharma, 1998; Nickells, 1996). 
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The ability of tumor cell populations to expand in number is determined not 
only by the rate of cell proliferation but also by the rate of cell attrition. Programmed 
cell death—apoptosis—represents a major source of this attrition (Douglas Hanahan 
& Robert A. Weinberg, 2000a). If this equilibrium is disturbed, one of two 
potentially fatal disorders occurs: (Potten & Wilson, 2004) the cells are dividing 
faster than they die, effectively developing a tumor (Bevec, Cavalli, Cavalli, & 
Bacher, 2010; Potten & Wilson, 2004), which is the hallmark of most and perhaps all 
types of cancer (Douglas Hanahan & Robert A. Weinberg, 2000a), and the cells are 
dividing slower than they die, which results in a disorder of cell loss (Bevec, et al., 
2010; Potten & Wilson, 2004). 
The life of most cells is in part maintained by cell–matrix and cell–cell 
adherence-based survival signals whose abrogation elicits apoptosis (Giancotti & 
Ruoslahti, 1999; Ishizaki, Cheng, Mudge, & Raff, 1995). Both soluble and 
immobilized apoptotic regulatory signals likely reflect the needs of tissues to 
maintain their constituent cells in appropriate architectural configurations (D. 
Hanahan & R. A. Weinberg, 2000). 
Resistance to apoptosis can be acquired by cancer cells through a variety of 
strategies. Surely, the most commonly occurring loss of a proapoptotic regulator 
through mutation involves the p53 tumor suppressor gene (Douglas Hanahan & 
Robert A. Weinberg, 2000a) that arrests the cell cycle in G1 in response to damaged 
DNA and is required for apoptosis induced by a variety of stimuli (Bjornsti & 
Osheroff, 1999; Camden, 2001b; Harris, 1996). 
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1.3.2 Historically: 
The cell death is a completely normal process in living organisms and was 
already discovered by scientists more than 100 years ago. The German scientist Carl 
Vogt was first to describe the principle of apoptosis in 1842. In 1885, anatomist 
Walther Flemming delivered a more precise description of the process of 
programmed cell death. However, it was not, until 1965, resurrected. Apoptosis 
(Greek: apo - from, ptosis - falling) was distinguished from traumatic cell death by 
John Foxton Ross Kerr at the University of Queensland in 1965 (Potten & Wilson, 
2004). The possibility that apoptosis serves as a barrier to cancer was first raised in 
1972, when Kerr, Wyllie, and Currie described massive apoptosis in the cells 
populating rapidly growing, hormone-dependent tumors following hormone 
withdrawal (Kerr, Wyllie, & Currie, 1972). 
 
 
 
 
 
 
 
 
 13 
1.4 DNA Structure: 
 1.4.1 DNA Overview: 
a. Introduction: 
Deoxyribonucleic acid (DNA) is a nucleic acid that contains the 
genetic instructions used in the development and functioning of all known living 
organisms and some viruses. The main role of DNA molecules is the long-term 
storage of information. DNA segments that carry the genetic information are called 
genes, but other DNA sequences have structural purposes, or are involved in 
regulating the use of this genetic information (Calladine, Drew, Luisi, & Travers, 
2004). 
DNA can be damaged by many sorts of mutagens, which change the DNA 
sequence. Mutagens include oxidizing agents, alkylating agents and also high-energy 
electromagnetic radiation such as ultraviolet light and X-rays (Jeffrey, 1985). 
DNA chain is 22 to 26 Angstroms (Å) wide (2.2 to 2.6 nanometres), and one 
nucleotide unit is 3.3 Å (0.33 nm) long (Watson & Crick, 1953). Although each 
individual repeating unit is very small, DNA polymers can be very large molecules 
containing millions of nucleotides. For instance, the largest human chromosome, 
chromosome number 1, is approximately 220 million base pairs long (Mandelkern, 
Elias, Eden, & Crothers, 1981). 
b. DNA’s Discovery: 
DNA was first isolated by the Swiss physician Friedrich Miescher in 
1869 that he called it at that time by "nuclein" but two years earlier, the Czech monk 
 14 
Gregor Mendel, had closely connected to the finding of nuclein by studying the traits 
in the peas and their inherit. In 1919, the molecular structure of DNA had been 
discovered by Phoebus Levene. He identified the base, sugar and phosphate 
nucleotide unit (Levene, 1919) and he thought that the chain was short and the bases 
repeated in a fixed order. In 1928, Frederick Griffith discovered that the DNA carried 
genetic information. Later on, William Astbury, in 1937, produced the first X-ray 
diffraction patterns that showed that DNA had a regular structure (Maddox, 2003). 
Oswald Avery, along with coworkers Colin MacLeod and Maclyn McCarty, 
identified DNA as the transforming principle in 1943 (Meselson & Stahl, 1958).  
In the late 1940's, the scientific were skeptical that DNA was most likely the 
molecule of life, they also knew that DNA included different amounts of the four 
bases adenine, thymine, guanine and cytosine (usually abbreviated A, T, G and C), 
but nobody had the slightest idea of what the molecule might look like (Fredholm, 
2003). 
In order to solve this puzzle, a couple of distinct pieces of information needed 
to be put together. One was that the phosphate backbone was on the outside with 
bases on the inside; another that the molecule was a double helix. It was also 
important to Figure out that the two strands run in opposite directions and that the 
molecule had a specific base pairing (Fredholm, 2003). 
In 1953 James D. Watson and Francis Crick suggested the first correct 
double-helix model of DNA structure (Watson & Crick, 1953), Figure 1.3. Their 
double-helix, molecular model of DNA was then based on a single X-ray diffraction 
image (F. Crick & Watson, 1953) taken by Rosalind Franklin and Raymond Gosling 
in May 1952, as well as the information that the DNA bases were paired—also 
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obtained through private communications from Erwin Chargaff in the previous years. 
Chargaff's rules played a very important role in establishing double-helix 
configurations for B-DNA as well as A-DNA. 
In 1957, Crick laid out the "Central Dogma" of molecular biology, which 
foretold the relationship between DNA, RNA, and proteins (F. H. C. Crick, 1957, 
1958; Strasser, 2006), and articulated the "adaptor hypothesis" (F.H.C. Crick, 1955). 
Final confirmation of the replication mechanism in 1958, the discovery of the codons 
by Crick and coworkers and the decipher of the genetic code by Har Gobind 
Khorana, Robert W. Holley and Marshall Warren Nirenberg (Nobelprize.org, 1968)  
lead to the birth of molecular biology (Friedberg, 2002; Hayes, 1985; Ingram, 2002). 
 
 
Figure 1.3 The original DNA model by Watson and Crick Photo: Cold Spring 
Harbor Laboratory Archives (F. Crick & Watson, 1953). 
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1.4.2 Properties: 
DNA consists of two long polymers (Alberts, 2002; Butler, 2000; Saenger, 
1984) that are held tightly together (Berg, Tymoczko, & Stryer, 2002; Gregory et al., 
2006) by simple units, nucleotides, in the shape of a double helix (Moss, 1970). This 
double helix contains both the segment of the backbone of the molecule, which holds 
the chain together, and a base, which interacts with the other DNA strand in the 
helix. A base linked to a sugar is called a nucleoside and a base linked to a sugar and 
one or more phosphate groups is called a nucleotide. If multiple nucleotides are 
linked together, as in DNA, this polymer is called a polynucleotide (Moss, 1970). 
The backbone of the DNA strand is made from alternating phosphate and 
sugar residues (Ghosh & Bansal, 2003). The sugar in DNA is pentose 2-deoxyribose 
that differs from RNA which has pentose sugar ribose (Berg, et al., 2002). The 
sugars are joined together by phosphate groups that form phosphodiester bonds 
between the third and fifth carbon atoms of adjacent sugar rings. These asymmetric 
bonds mean a strand of DNA has a direction. In a double helix the direction of the 
nucleotides in one strand is opposite to their direction in the other strand therefore 
are antiparallel. The asymmetric ends of DNA strands are called the 5′ (five prime) 
and 3′ (three prime) ends, with the 5’ end having a terminal phosphate group and the 
3’ end a terminal hydroxyl group. 
The DNA double helix is stabilized by hydrogen bonds between the bases 
attached to the two strands. The four bases found in DNA are adenine (abbreviated 
A), cytosine (C), guanine (G) and thymine (T). These four bases are attached to the 
sugar/phosphate to form the complete nucleotide (Keller, 2007), see Figure 1.4. 
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The sequence of these four bases along the backbone encodes information. 
This information is read using the genetic code, which specifies the sequence of the 
amino acids within proteins. The code is read by copying stretches of DNA into the 
related nucleic acid RNA, in a process called transcription. 
The four bases are classified into two types; adenine and guanine are fused 
five- and six-membered heterocyclic compounds called purines, while cytosine and 
thymine are six-membered rings called pyrimidines (Berg, et al., 2002; Clausen-
Schaumann, Rief, Tolksdorf, & Gaub, 2000). A fifth pyrimidine base, called uracil 
(U), usually takes the place of thymine in RNA and differs from thymine by lacking 
a methyl group on its ring. Uracil is not usually found in DNA, occurring only as a 
breakdown product of cytosine. In addition to RNA and DNA, a large number of 
artificial nucleic acid analogues have also been created to study the proprieties of 
nucleic acids, or for use in biotechnology (Verma & Eckstein, 1998). 
 
Figure 1.4 The Chemical structure of DNA. Hydrogen bonds shown as dotted lines (Keller, 
2007; Madeleine Price Ball, 2007). 
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a. Grooves: 
Double helix may be found by tracing the spaces, or grooves, between 
the strands. These voids are adjacent to the base pairs and may provide a binding site. 
As the strands are not directly opposite each other, the grooves are unequally sized. 
One groove, the major groove, is 22 Å wide and the other, the minor groove, is 12 Å 
wide (Calladine, et al., 2004; Wing et al., 1980), Figure 1.5. The narrowness of the 
minor groove means that the edges of the bases are more accessible in the major 
groove. This situation varies in unusual conformations of DNA within the cell, but 
the major and minor grooves are always named to reflect the differences in size that 
would be seen if the DNA is twisted back into the ordinary B form. 
 
Figure 1.5 The groove of DNA structure (Zygote Media Group, 2007). 
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 b. Base pairing: 
Each type of base on one strand forms a bond with just one type of 
base on the other strand. This is called complementary base pairing. Here, purines 
form hydrogen bonds to pyrimidines, with A bonding only to T, and C bonding only 
to G. This arrangement of two nucleotides binding together across the double helix is 
called a base pair (Clausen-Schaumann, et al., 2000). The two types of base pairs 
form different numbers of hydrogen bonds, AT forming two hydrogen bonds, and 
GC forming three hydrogen bonds, as shown in figure 1.4. 
c. Supercoiling: 
 DNA can be twisted like a rope in a process called DNA supercoiling. 
With DNA in its "relaxed" state, a strand usually circles the axis of the double helix 
once every 10.4 base pairs, but if the DNA is twisted the strands become more tightly 
or more loosely wound (Benham & Mielke, 2005). If the DNA is twisted in the 
direction of the helix, this is positive supercoiling, and the bases are held more 
tightly together. If they are twisted in the opposite direction, this is negative 
supercoiling, and the bases come apart more easily. In nature, most DNA has slight 
negative supercoiling that is introduced by topoisomerases enzymes (Champoux, 
2001) that also included to relieve the twisting stresses during transcription and DNA 
replication (Wang, 2002).  
d. Alternate DNA structures: 
DNA exists in many possible conformations that include A-DNA, B-
DNA, and Z-DNA forms, although, only B-DNA and Z-DNA have been directly 
observed in functional organisms (Ghosh & Bansal, 2003) as in Figure 1.6. The 
conformation that DNA adopts depends on the hydration level, DNA sequence, the 
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amount and direction of supercoiling, chemical modifications of the bases, the type 
and concentration of metal ions, as well as the presence of polyamines in solution 
(Basu, Feuerstein, Zarling, Shafer, & . 1988). 
 
Figure 1.6 From left to right, the structures of A, B and Z DNA (Arnott, Chandrasekaran, 
Birdsall, Leslie, & Ratliff, 1980; R. Chandrasekaran & Arnott, 1996; R Chandrasekaran et 
al., 1989). 
The `B-DNA form' is most common under the conditions found in cells (I. C. 
Baianu, 1980; Leslie, Arnott, Chandrasekaran, & Ratliff, 1980) that occur at the high 
hydration levels present in living cells (I. Baianu, 1978; Gaylord & Kaufman, 1963). 
Compared to B-DNA, the A-DNA form is a wider right-handed spiral, with a 
shallow, wide minor groove and a narrower, deeper major groove. The A form 
occurs in the cell due to the hybrid pairings of DNA and RNA strands, as well as in 
enzyme-DNA complexes (Lu, Shakked, & Olson, 2000; Wahl & Sundaralingam, 
1997). Segments of DNA where the bases have been chemically modified by 
methylation may undergo a larger change in conformation and adopt the Z form. 
Here, the strands turn about the helical axis in a left-handed spiral, the opposite of the 
more common B form (Rothenburg, Koch-Nolte, & Haag, 2001). These unusual 
structures can be recognized by specific Z-DNA binding proteins and may be 
involved in the regulation of transcription (Oh, Kim, & Rich, 2002). 
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1.5 Cancer Treatment: 
1.5.1  Introduction: 
The treatment given for cancer is highly variable and dependent on a number 
of factors including the type, location and amount of disease and the health status of 
the patient. The treatments are designed to directly kill and/or remove the cancer 
cells or lead to their eventual death by stopping the cell division. Other treatments 
work by stimulating the body defence mechanisms (Cancer Request, 2010d). 
The standard methods of treating cancer include surgery, radiation therapy, 
chemotherapy, hormonal therapy (Camden, 2001b; Fayed, 2009; Lam, 2001; 
Maranga, 2009; Mishra, 2009), immunotherapy and monoclonal antibody therapy 
(Camden, 2001a, 2001b; Fayed, 2009; Maranga, 2009). In medical science, different 
cancer treatments are used in combination, either simultaneously or sequentially 
(Cancer Request, 2010d)depending on the type, size, location, and stage of the 
tumour in additional to the person's general health (Mishra, 2009). 
a. Surgical Intervention 
Surgery is the oldest form of treatment for many solid tumours 
(Cancer Request, 2010d; Mishra, 2009) It is used to prevent, treat and diagnose 
cancer (Fayed, 2009), which involves the complete removal of tumour or as much of 
the cancerous tissue as possible (Mishra, 2009). This is usually the first preference by 
the physicians; however, it is not helpful if the cancer has already metastasise to a 
remote area (Cancer Request, 2010d; Fayed, 2009; Selvan, 2007 ). Surgery is often 
performed in conjunction with chemotherapy or radiation therapy (Fayed, 2009; 
Maranga, 2009; Park & Posner, 2003; Selvan, 2007 ). 
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b. Radiation Therapy 
This type of treatment uses certain types of ionized energy beams or 
waves such as gamma rays or x-ray to shrink tumours and/or eliminate cancer cells 
(Cancer Request, 2010d; Fayed, 2009; Maranga, 2009; Mishra, 2009; Selvan, 2007 ). 
It works by damaging their genetic constitutes and making it unable to multiply 
(Fayed, 2009; Maranga, 2009). This type of cancer treatment is given in fractions in 
order to allow healthy tissue to recover between remission periods (Maranga, 2009). 
Radiotherapy may be used in conjunction with surgery and/or drug treatments 
(Cancer Request, 2010d; Mundt & Roeske, 2003). 
c. Chemotherapy 
It is a term used for a wide variety of medicines that are used to kill 
cancer cells by damaging the dividing cancer cells and preventing their further 
reproduction (Cancer Request, 2010d; Maranga, 2009; Mishra, 2009). Systematic 
chemotherapy generally uses anticancer drugs that enter the bloodstream and reach 
all areas of the body, making this treatment potentially useful for cancer that has 
spread (Ewesuedo & Ratain, 2003; Mishra, 2009). This type of treatment will be 
discussed in details in the following part 1.5.2. 
d. Hormone Therapy 
Hormone therapy is used against certain type of cancers which are 
dependent on hormones as signals for their growth. This treatment includes the use 
of drugs that stop the production of certain hormones (Cancer Request, 2010d; 
Maranga, 2009; Mishra, 2009). The hormonal therapy also used in conjugation with 
surgery and/or radiation therapy. 
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e. Immunotherapy/Biological Response Modifiers 
It involves several strategies that promote naturally occurring proteins 
to stimulate our body's own immune system defence to fight cancer (Cancer Request, 
2010d; Maranga, 2009; Mishra, 2009; Selvan, 2007 ). These are considered as 
vaccines that usually contain proteins found on or produced by cancer cells. Thus 
treatment aims to increase the response of the body against the cancer cells (Cancer 
Request, 2010d; Gajewski, 2003). 
f. Targeted Therapy 
This class of drugs is relatively new in the treatment of cancer since 
1990. They work by targeting specific proteins and processes that are limited 
primarily to cancer cells or that are much more prevalent in cancer cells. Some types 
work by blocking the biological processes that allow the tumour to thrive and grow, 
which are antibodies. Others cut off the blood supply to the tumour, angiogenesis, 
causing it to basically starve and die. This type of treatment is usually given in 
conjunction with other cancer treatments (Cancer Request, 2010d; Fayed, 2009). 
g. Complementary and Alternative Medicines 
These treatment methods are not practiced by conventional western 
medicine, usually used in the South East Asia. They can include herbal, animal 
derived, and mind-body approaches to treating cancer (Cancer Request, 2010d). 
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1.5.2  Chemotherapy: 
The term chemotherapy, currently used cytotoxic drugs, refers to a wide 
range of drugs used to treat cancer which affect rapidly dividing cells (Cancer 
Request, 2010b; Ingwersen, 2001). Unlike surgery, chemotherapy affects the entire 
body by targeting rapidly multiplying cells (Camden, 2001b; Fayed, 2009; 
Ingwersen, 2001; Maranga, 2009). Ideally cytotoxic agents that have specificity for 
cancer cells while not affecting normal cells, would be extremely desirable (Camden, 
2001a, 2001b; Ingwersen, 2001). Nevertheless, the treatment of cancer by cytotoxic 
drugs produces some of the common side-effects, like hair loss and vomiting, 
because of the death of normal cells (Baquiran & Gallagher, 2001; Camden, 2001b; 
Cancer Request, 2010b; Fayed, 2009; Maranga, 2009). 
There are many universal cytotoxic drugs that are used to treat cancer; based 
on their chemical structures and the way they act on cancer cells (SEER Training 
Modules, 2011a). These chemotherapeutic agents can be divided as follows, 
(Camden, 2001a; Fayed, 2009; Skeel, 2007): 
a. Antimetabolites:  
Are drugs that interfere with the formation of key bio-molecules 
within the cell including nucleotides, the building blocks of DNA. These will 
interfere with DNA replication and therefore cell division (Baquiran & Gallagher, 
2001; Cancer Request, 2010b; Ingwersen, 2001). 
 
 
 25 
b. Genotoxic Drugs:  
Drugs that damage DNA that eventually interfere with DNA 
replication and cell division (Baquiran & Gallagher, 2001; Cancer Request, 2010b). 
c. Spindle Inhibitors: 
 These agents prevent proper cell division by interfering with the 
cytoskeletal components that enable one cell to divide into two (Baquiran & 
Gallagher, 2001; Cancer Request, 2010b). 
d. Other Chemotherapy Agents:  
These agents inhibit cell division by mechanisms that are not covered 
in the three categories listed above (Baquiran & Gallagher, 2001; Cancer Request, 
2010b). 
 
1.6 Genotoxic Drugs: 
 1.6.1 Introduction: 
These drugs affect nucleic acids and alter their function either directly 
through binding to DNA or indirectly through enzymes involved in DNA replication 
lead to DNA damage. Cancer cells are particularly sensitive to genotoxic agents 
because they are actively synthesizing new DNA and if enough damage occurs, will 
often undergo apoptosis (Cancer Request, 2010c; Ewesuedo & Ratain, 2003). These 
agents in addition to being cytotoxic (cell poisoning and having the ability to kill the 
cell), are also mutagenic and carcinogenic (Cancer Request, 2010c). 
